Here’s everything to expect from the Fed’s policy announcement Wednesday
The Fed meeting will conclude with the central bank not doing a whole lot of anything — just the way the market wants things for now.
Trump sues Michigan official in a bid to keep his name on state’s ballots in 2024
Lawsuits in multiple states argue that Trump should be disqualified in 2024 due to his role in fomenting the Jan. 6, 2021, insurrection at the U.S. Capitol.
How to play a possible global electric vehicle meltdown, according to Deutsche Bank
Deutsche Bank gave its picks amid concerns of a global electric vehicle meltdown.
Before the Fed decision, all eyes will be on this big Treasury debt announcement Wednesday
With debt, deficits and bond yields all surging, investors are watching closely how the government will go to market with its borrowing needs.
SEC sues SolarWinds over massive cyberattack, alleging fraud and weak controls
Information technology firm SolarWinds committed fraud and failed to maintain adequate internal controls for years, the SEC alleged in a lawsuit.
JetBlue sinks to 12-year low as airline forecasts more losses, Spirit antitrust trial begins
JetBlue faces the Justice Department in an antitrust trial over the carrier’s proposed acquisition of budget carrier Spirit Airlines.
UAW strikes cost Stellantis about $3.2 billion in revenue
Stellantis has announced tentative agreements with both the UAW and Unifor unions since Saturday. However, members must still ratify the deals.
Markets are on board with the Fed’s ‘higher for longer’ policy, CNBC survey shows
Respondents, including economists, strategists and analysts, believe the Fed is now on hold into September of next year.
62% of Americans are still living paycheck to paycheck, making it ‘the main financial lifestyle,’ report finds
The number of workers who say they are stretched thin has remained stubbornly high as inflation weighs on American households.
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
The results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
